C12N 5/0636
T lymphocytes
Official title: {T lymphocytes}
C12N5/0636 (T lymphocytes) appears on 3,657 US grants and 8,275 published applications in this corpus.
Search patents in C12N- Granted patents
- 3,657
- Published applications
- 8,275
- Assignees
- 2,024
- Inventors
- 10,773
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 5 | 0 |
| 1994 | 5 | 0 |
| 1995 | 7 | 0 |
| 1996 | 3 | 0 |
| 1997 | 7 | 0 |
| 1998 | 21 | 0 |
| 1999 | 13 | 0 |
| 2000 | 12 | 0 |
| 2001 | 16 | 10 |
| 2002 | 15 | 45 |
| 2003 | 18 | 58 |
| 2004 | 18 | 51 |
| 2005 | 12 | 39 |
| 2006 | 10 | 41 |
| 2007 | 8 | 37 |
| 2008 | 14 | 47 |
| 2009 | 19 | 62 |
| 2010 | 29 | 100 |
| 2011 | 31 | 108 |
| 2012 | 35 | 73 |
| 2013 | 36 | 82 |
| 2014 | 63 | 118 |
| 2015 | 75 | 146 |
| 2016 | 76 | 192 |
| 2017 | 95 | 320 |
| 2018 | 186 | 421 |
| 2019 | 262 | 654 |
| 2020 | 337 | 709 |
| 2021 | 378 | 864 |
| 2022 | 353 | 965 |
| 2023 | 323 | 857 |
| 2024 | 420 | 897 |
| 2025 | 444 | 817 |
| 2026 | 305 | 562 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Inducible chimeric antigen receptor and application thereof6 Oct 2026US 12,752,007 B2Beijing Tiantan Hospital, Capital Medical University
- CCR4 targeted chimeric antigen receptor modified T cells for treatment of CCR4 positive malignancies6 Oct 2026US 12,753,219 B2City of Hope
- Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy6 Oct 2026US 12,753,220 B2Cellectis
- Composition for inducing immunotolerance8 Oct 2026US 2026/0306540 A1
- Novel phosphoantigen prodrug compound and use thereof8 Oct 2026US 2026/0306541 A1
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Chimeric receptors8 Oct 2026US 2026/0306631 A1St. Jude Children?S Research Hospital
- Chimeric Cytokine Receptors and Methods of Use8 Oct 2026US 2026/0308235 A1
Most cited
By later US patents
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Methods for selectively stimulating proliferation of T cells452US 6,534,055 B1Genetics Institute, Inc. · 2003
- Simultaneous stimulation and concentration of cells422US 6,797,514 B2XCYTE Therapies, Inc. · 2004
- Simultaneous stimulation and concentration of cells398US 6,867,041 B2XCYTE Therapies, Inc. · 2005
- Methods of treating HIV infected subjects386US 6,905,680 B2Genetics Institute, Inc. · 2005